Breakthrough Long COVID Biomarker Identified By Aethlon Medical (Nasdaq: AEMD) Opens Door For Hemopurifier Treatment
Aethlon Medical, Inc. (Nasdaq: AEMD ) today announced publication of new peer-reviewed research in theInternational Journal of Molecular Sciencesdemonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Company's Hemopurifier(R).
The study, conducted in collaboration with investigators from the University of California, San Francisco (UCSF), provides what we believe is new evidence supporting extracellular vesicles as a potential therapeutic target in Long COVID and helps establish a translational framework for future studies evaluating whether the Hemopurifier can remove disease-associated EVs and their molecular cargo.
AdvertisementKey FindingsAmong the study's principal findings:
- Patients with Long COVID had approximately two-fold higher levels of mannose-positive extracellular vesicles than individuals who recovered fully following COVID-19 infection. Small extracellular vesicles carrying disease-associated glycosylation patterns were successfully captured using GNA affinity resin, the active binding component of the Hemopurifier. GNA affinity resin treatment significantly reduced seven circulating microRNAs associated with immune regulation and inflammatory signaling. Computational pathway analysis suggested modulation of several biologically relevant signaling pathways implicated in Long COVID, including JAK-STAT, VEGF, PI3K, and Estrogen signaling. The findings help establish a mechanistic link between disease-associated extracellular vesicles and the Hemopurifier's lectin-based capture technology.
The research analyzed plasma samples from participants enrolled in UCSF's Long-term Impact of Infection with Novel Coronavirus (LIINC) study.
The full peer-reviewed article, titled"Increased Mannosylation of Extracellular Vesicles in Long COVID Plasma as a Binding Target for Galanthus nivalis Agglutinin (GNA) Affinity Resin,"appears in theInternational Journal of Molecular Sciencesat
About Aethlon and the Hemopurifier(R)Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device that is designed to combat cancer and life-threatening viral infections, and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses, and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Additional information can be found at.
Aethlon Medical, Inc. (Nasdaq: AEMD ) is a featured biotech stock on Investorideas
More info on AEMD at Investorideas Visit:
Get News Alerts on Aethlon Medical
Disclaimer/Disclosure: Aethlon Medical, Inc. is a paid featured medical tech stock on Investorideas disclosure: Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more disclosure: Contact management and IR of each company directly regarding specific questions.
Research biotech stocks at Investorideas free stock directory
>
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment